Literature DB >> 16125386

Synthesis, stability, and implications of phosphothioate agonists of sphingosine-1-phosphate receptors.

Frank W Foss1, Jeremy J Clemens, Michael D Davis, Ashley H Snyder, Molly A Zigler, Kevin R Lynch, Timothy L Macdonald.   

Abstract

Phosphothioates may provide metabolic stability when compared to their phosphate counterparts, while retaining the potency and efficacy as agonists at sphingosine-1-phosphate (S1P) G-protein coupled receptors. Unlike their phosphate precursors, phosphothioate compounds with S1P-receptor profiles similar to that of FTY720, an emerging immunomodulator, were shown to evoke prolonged lymphopenia in vivo. Analysis of mouse plasma concentrations for a series of related alcohol/phosphate/phosphothioate compounds showed the conversion of the phosphate to alcohol. These preliminary data highlight the importance of metabolic regulation of S1P receptor ligands.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16125386     DOI: 10.1016/j.bmcl.2005.07.057

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

1.  Pulmonary endothelial cell barrier enhancement by novel FTY720 analogs: methoxy-FTY720, fluoro-FTY720, and β-glucuronide-FTY720.

Authors:  Sara M Camp; Eddie T Chiang; Chaode Sun; Peter V Usatyuk; Robert Bittman; Viswanathan Natarajan; Joe G N Garcia; Steven M Dudek
Journal:  Chem Phys Lipids       Date:  2015-08-10       Impact factor: 3.329

2.  Interaction of integrin β4 with S1P receptors in S1P- and HGF-induced endothelial barrier enhancement.

Authors:  Xiuqin Ni; Yulia Epshtein; Weiguo Chen; Tingting Zhou; Lishi Xie; Joe G N Garcia; Jeffrey R Jacobson
Journal:  J Cell Biochem       Date:  2014-06       Impact factor: 4.429

Review 3.  Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury.

Authors:  Viswanathan Natarajan; Steven M Dudek; Jeffrey R Jacobson; Liliana Moreno-Vinasco; Long Shuang Huang; Taimur Abassi; Biji Mathew; Yutong Zhao; Lichun Wang; Robert Bittman; Ralph Weichselbaum; Evgeny Berdyshev; Joe G N Garcia
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

Review 4.  Immune mechanisms and novel pharmacological therapies of acute kidney injury.

Authors:  Amandeep Bajwa; Gilbert R Kinsey; Mark D Okusa
Journal:  Curr Drug Targets       Date:  2009-12       Impact factor: 3.465

5.  Sphingosine 1-phosphate receptor 1 (S1P(1)) upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P(1) antagonist.

Authors:  Stuart M Cahalan; Pedro J Gonzalez-Cabrera; Nhan Nguyen; Miguel Guerrero; Elizabeth A George Cisar; Nora B Leaf; Steven J Brown; Edward Roberts; Hugh Rosen
Journal:  Mol Pharmacol       Date:  2012-11-30       Impact factor: 4.436

6.  Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs.

Authors:  Frank W Foss; Thomas P Mathews; Yugesh Kharel; Perry C Kennedy; Ashley H Snyder; Michael D Davis; Kevin R Lynch; Timothy L Macdonald
Journal:  Bioorg Med Chem       Date:  2009-04-12       Impact factor: 3.641

Review 7.  Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions.

Authors:  Abby L Parrill; Gabor Tigyi
Journal:  Biochim Biophys Acta       Date:  2012-09-12

Review 8.  [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].

Authors:  J Klatt; H-P Hartung; R Hohlfeld
Journal:  Nervenarzt       Date:  2007-10       Impact factor: 1.214

9.  Sphingosine 1-phosphate pKa and binding constants: intramolecular and intermolecular influences.

Authors:  Mor M Naor; Michelle D Walker; James R Van Brocklyn; Gabor Tigyi; Abby L Parrill
Journal:  J Mol Graph Model       Date:  2007-03-14       Impact factor: 2.518

10.  FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology.

Authors:  Kunitomo Adachi; Kenji Chiba
Journal:  Perspect Medicin Chem       Date:  2007-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.